Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2371 | Microcrystalline Cellulose, NF Wiki | 0.71 |
| drug856 | Carotid Artery Reactivity Testing Wiki | 0.71 |
| drug2916 | Placebo Wiki | 0.03 |
Navigate: Correlations HPO
There are 2 clinical trials
The primary aim of this study is to determine whether Camostat mesylate reduces SARS-COV-2 associated coagulopathy. Additional aims are to determine the effect of Camostat mesylate on SARS-COV-2 associated myocardial injury, to assess duration of hypoxia or intubation, to evaluate the length of intensive care unit and hospital stay, and assess mortality rates.
Description: The sum percent change in D-Dimer over 7 days will be compared to day 1
Measure: Percent change in plasma D-Dimer Time: 7 daysDescription: The first assessment on mortality and complications will be carried out 3 months after the start of the study.
Measure: Overall Safety and adverse event Time: 3 monthsDescription: Percent change in fibrinogen over 7 days compared to day 1
Measure: Change in plasma Fibrinogen levels Time: 7 daysDescription: Percent change in troponin over 7 days compared to day 1
Measure: Change in plasma troponin Time: 7 daysDescription: New onset cardiomyopathy defined by a reduction of EF by greater than 10% or less than 45% will be measured
Measure: New onset cardiomyopathy Time: 7 daysDescription: Days with hypoxia (Room Air O2 Sat<93%) or days intubated
Measure: Duration of intubation Time: 7 daysDescription: The number of days in the intensive care unit
Measure: Length of stay in the intensive care unit Time: 28 daysDescription: The number of days since admission to discharge
Measure: Time to discharge from hospital Time: 30 daysDescription: The ocurrence of major adverse cardiovascular events (MACE): MI, stroke, CHF, PCI, death from cardiovascular disease will be studied.
Measure: Occurrence of major adverse cardiovascular events Time: 7 daysThe overall objective of the study is to determine the therapeutic effect and tolerance of Camostat mesylate, compared to placebo in adult patients with ambulatory COVID-19 disease, presenting with risk factors of severe COVID-19. Camostat mesylate is a serine protease TMPRSS2 (Transmembrane Serine Protease 2) inhibitor which has been successfully and safely used to treat pancreatitis-associated pain and post-operative reflux oesophagitis in Japan. More recently, it has been shown to inhibit SARS-CoV-2 viral entry and reduce infection of human primary pneumocytes and lung cell lines. Camostat mesylate or placebo will be administered to consenting adult patients with virologically confirmed COVID-19, not requiring initial hospitalization. All patients will receive standard of care along with randomized treatments. Outcomes of included patients will be compared between the 2 groups.
Description: Proportion of patients hospitalized for COVID-19 deterioration or who died without hospitalization
Measure: Hospitalization for COVID-19 deterioration or death without hospitalization Time: Day 21Description: Number of patients with at least one adverse event
Measure: Adverse events Time: Day 21Description: Number of patients with at least one serious adverse event
Measure: Serious adverse events Time: Day 21Description: Number of patients who discontinued the investigational medication
Measure: Investigational medication discontinuation Time: Day 21Description: Proportion of patients hospitalized for COVID-19 deterioration (reviewed by independent adjudication comitter) or who died without hospitalization
Measure: Hospitalization for COVID-19 deterioration or death without hospitalization, evaluated by independent adjudication comittee Time: Day 21Description: WHO clinical scale: Uninfected - No clinical or virological evidence of infection: 0; Ambulatory - No limitation of activities: 1; Ambulatory - limitation of activities: 2; Hospitalized - no oxygen therapy: 3; Hospitalized - oxygen by mask or nasal prongs: 4; Hospitalized; oxygen by non invasive ventilation or High flow: 5; Intubation and Mechanical ventilation: 6; Mechanical ventilation + additional organ support (pressors, Renal replacement therapy, ECMO):7; Dead: 8
Measure: Clinical improvement using the Word Health Organization (WHO) COVID-19 scale Time: Day 7, 14, 21Description: Proportion of patients admitted to an intensive care unit
Measure: Need for intensive care Time: Day 21Description: Number of days alive without hospitalization up to day 21
Measure: Duration of hospitalization Time: Day 21Description: Proportion of patients with initiation of invasive mechanical ventilation
Measure: Need for invasive mechanical ventilation for severe COVID-19 Time: Day 21Description: Proportion of patients with initiation of oxygen therapy
Measure: Need for oxygen therapy for COVID-19 Time: Day 21Description: Proportion of patients alive at day 90
Measure: Overall survival Time: Day 90Description: Number of days alive without symptoms at day 21
Measure: Duration of symptoms Time: Day 21Description: By Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) on nasal swab and droplet quantification of SARS-CoV2 ribonucleic acid-emia (RNAemia)
Measure: SARS-CoV-2 virological assessment Time: Day 7, 14, 21Description: SARS-CoV2 antibodies quantification in blood
Measure: SARS-CoV-2 serological assessment Time: Day 7, 14, 21 and 90Description: Peripheral blood lymphocyte phenotyping with telomere length measurement
Measure: Peripheral blood lymphocyte phenotyping Time: Day 1, 14, 90Description: Acute kidney failure defined as at least serum creatinine increase of 0.3mg/dl or 1.5-1.9 times baseline and/or oliguria < 0.5ml/kg/h
Measure: Acute kidney failure Time: Day 21Description: estimated glomerular filtration rate
Measure: Renal function Time: Day 7, 14 and 21Description: Uricemia in mmol/L or mg/dL
Measure: Concentration of urea in blood Time: Day 7, 14 and 21Description: Kaliemia in mmol/L
Measure: Concentration of potassium in blood Time: Day 7, 14 and 21Description: Liver transaminases dosage on blood sample
Measure: Liver function Time: Day 7, 14 and 21Description: Gamma-glutamyl transferase (gamma-GT) dosage on blood sample
Measure: Liver function (2) Time: Day 7, 14 and 21Description: Biobanking of blood samples for predictive biomarker assessment
Measure: Biobanking for biomarker assessment Time: Day 1, 7, 14, 21, 90Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports